Lin Tan

机构：The University of Texas MD Anderson Cancer Center, Shenzhen Bay Laboratory, University of Hong Kong - Shenzhen Hospital, University of Hong Kong · ORCID：0000-0003-3549-0401

发表论文 34 篇 · 总被引 486 次 · h-index 13

代表论文

• The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy (2022 · Molecular Cancer · 被引 61)
• Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9 (2022 · Acta Pharmacologica Sinica · 被引 30)
• In Vitro and In Vivo Antitumor Assay of Mitochondrially Targeted Fluorescent Half-Sandwich Iridium(III) Pyridine Complexes (2023 · Inorganic Chemistry · 被引 28)
• Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma (2021 · Frontiers in Genetics · 被引 24)
• A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of ALKBH7 (2022 · Frontiers in Genetics · 被引 21)
• High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer (2019 · Bioscience Reports · 被引 20)